. Author manuscript; available in PMC: 2020 Sep 1.

Published in final edited form as: Mol Cancer Ther. 2019 Dec 17;19(3):731–741. doi: 10.1158/1535-7163.MCT-19-0809

Table 1. The growth-inhibitory activity of silvestrol and 10 related rocaglates lacking the dioxanyl ring in NF1^+/+ STS26T and NF1^−/− ST8814 MPNST, Nf2^−/− schwannoma, and NF2^−/− meningioma cells.

The average IC₅₀ value of each rocaglate was determined by 3-day resazurin proliferation assays as described in Methods. Didesmethylrocaglamide (DDR) and rocaglamide (Roc) were found to possess growth-inhibitory activity similar to or more potent than silvestrol. ND, not determined.

Compound	MW (Da)	IC₅₀ (nM)
Compound	MW (Da)	Sch10545 Nf2^−/− schwannoma cells	Ben-Men-1 NF2^−/− meningioma cells	STS26T NF1^+/+ MPNST cells	ST8814 NF1^−/− MPNST cells
Silvestrol	654	70	10	10	40
8b-O-methyl-4’-demethoxy-3’,4’-methylenedioxyrocaglaol	462	>2,500	>2,500	5,000	10,000
Methyl 8b-O-methyl-4’-demethoxy-3’,4’-methylenedioxyrocaglate	520	1,900	3,800	1,300	2,000
Rocaglaol	434	60	100	40	90
Methyl rocaglate	492	50	55	25	35
4’-demethoxy-3’,4’-methylenedioxyrocaglaol	448	65	85	55	120
Methyl 4’-demethoxy-3’,4’-methylenedioxyrocaglate	506	60	80	35	70
8b-O-methylrocaglaol	448	>20,000	>20,000	>20,000	>20,000
Didesmethylrocaglamide	477	10	5	5	5
Methyl 8b-O-methylrocaglate	506	9,300	>10,000	>10,000	>20,000
Rocaglamide	506	ND	15	15	20

Table 1. The growth-inhibitory activity of silvestrol and 10 related rocaglates lacking the dioxanyl ring in NF1+/+ STS26T and NF1−/− ST8814 MPNST, Nf2−/− schwannoma, and NF2−/− meningioma cells.

Table 1. The growth-inhibitory activity of silvestrol and 10 related rocaglates lacking the dioxanyl ring in NF1^+/+ STS26T and NF1^−/− ST8814 MPNST, Nf2^−/− schwannoma, and NF2^−/− meningioma cells.